Nippon Life Global Investors Americas Inc. increased its position in Johnson & Johnson (NYSE:JNJ) by 7.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 168,006 shares of the company’s stock after acquiring an additional 12,030 shares during the period. Johnson & Johnson makes up 1.9% of Nippon Life Global Investors Americas Inc.’s portfolio, making the stock its 10th biggest position. Nippon Life Global Investors Americas Inc.’s holdings in Johnson & Johnson were worth $21,681,000 at the end of the most recent quarter.
Several other hedge funds have also recently added to or reduced their stakes in the stock. Peoples Financial Services CORP. increased its stake in Johnson & Johnson by 20.4% during the 3rd quarter. Peoples Financial Services CORP. now owns 30,668 shares of the company’s stock valued at $4,237,000 after buying an additional 5,190 shares during the period. Meeder Asset Management Inc. increased its stake in Johnson & Johnson by 29.1% during the 4th quarter. Meeder Asset Management Inc. now owns 98,256 shares of the company’s stock valued at $12,679,000 after buying an additional 22,157 shares during the period. QUANTRES ASSET MANAGEMENT Ltd acquired a new position in Johnson & Johnson during the 3rd quarter valued at about $829,000. Foundation Resource Management Inc. acquired a new position in Johnson & Johnson during the 3rd quarter valued at about $208,000. Finally, Vanguard Group Inc increased its stake in Johnson & Johnson by 1.5% during the 3rd quarter. Vanguard Group Inc now owns 213,433,449 shares of the company’s stock valued at $29,490,100,000 after buying an additional 3,235,861 shares during the period. 67.32% of the stock is currently owned by institutional investors and hedge funds.
NYSE:JNJ opened at $138.02 on Wednesday. Johnson & Johnson has a twelve month low of $118.62 and a twelve month high of $148.99. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.47 and a quick ratio of 1.20. The stock has a market cap of $366.27 billion, a PE ratio of 16.87, a price-to-earnings-growth ratio of 2.08 and a beta of 0.68.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 16th. The company reported $2.10 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.06 by $0.04. Johnson & Johnson had a net margin of 18.75% and a return on equity of 35.63%. The company had revenue of $20.02 billion during the quarter, compared to analyst estimates of $19.55 billion. During the same quarter last year, the firm posted $2.06 EPS. The business’s revenue for the quarter was up .1% on a year-over-year basis. Equities research analysts expect that Johnson & Johnson will post 8.58 earnings per share for the current year.
Several equities analysts have commented on the stock. Zacks Investment Research cut shares of Johnson & Johnson from a “buy” rating to a “sell” rating in a research note on Tuesday, December 18th. Citigroup raised their target price on shares of Johnson & Johnson from $139.00 to $147.00 and gave the company a “neutral” rating in a research note on Monday, February 25th. Morgan Stanley set a $140.00 target price on shares of Johnson & Johnson and gave the company a “hold” rating in a research note on Thursday, December 20th. Barclays reissued an “equal weight” rating and set a $135.00 target price (down previously from $137.00) on shares of Johnson & Johnson in a research note on Wednesday, January 23rd. Finally, Wells Fargo & Co restated an “outperform” rating and set a $152.00 price objective (down previously from $162.00) on shares of Johnson & Johnson in a research report on Monday, January 14th. Six analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $143.58.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: Dollar Cost Averaging
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.